TriangleIMPACT (NCT07148050)
IMPACT trial for Solid Tumor (Excluding CNS) (NCT07148050). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Some childhood solid tumors, liver cancers, Wilms tumor, rhabdomyosarcoma, share a protein called glypican-3. When they return, few options remain.
The idea: aim engineered T cells at that protein, give them their own fuel, and build in an off switch.
At Seattle Children's, a child's T cells receive a receptor for glypican-3 together with genes for interleukin-15 and interleukin-21, signals that help them persist inside a solid tumor, where CAR T cells usually fade. In the lab, that combination killed tumor cells better than the receptor alone. A safety gene lets doctors eliminate the cells with a drug if side effects demand it.
IMPACT is an early safety study, ages one to twenty-six. Michelle Choe leads it. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.